Nothing Special   »   [go: up one dir, main page]

WO2005107871A3 - Pyrroloquinoline quinone drugs for treatment of cardiac injury - Google Patents

Pyrroloquinoline quinone drugs for treatment of cardiac injury Download PDF

Info

Publication number
WO2005107871A3
WO2005107871A3 PCT/US2005/015742 US2005015742W WO2005107871A3 WO 2005107871 A3 WO2005107871 A3 WO 2005107871A3 US 2005015742 W US2005015742 W US 2005015742W WO 2005107871 A3 WO2005107871 A3 WO 2005107871A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
cardiac injury
pyrroloquinoline quinone
drugs
prevention
Prior art date
Application number
PCT/US2005/015742
Other languages
French (fr)
Other versions
WO2005107871A2 (en
Inventor
Paul J Davis
Joel S Karliner
Original Assignee
Clf Medical Technology Acceleration Program Inc
Paul J Davis
Joel S Karliner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clf Medical Technology Acceleration Program Inc, Paul J Davis, Joel S Karliner filed Critical Clf Medical Technology Acceleration Program Inc
Priority to CA002565616A priority Critical patent/CA2565616A1/en
Priority to JP2007511607A priority patent/JP2007536256A/en
Priority to AU2005240650A priority patent/AU2005240650A1/en
Priority to EP05745030A priority patent/EP1750805A2/en
Publication of WO2005107871A2 publication Critical patent/WO2005107871A2/en
Publication of WO2005107871A3 publication Critical patent/WO2005107871A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention includes compositions comprising purified pyrrologuinoline guinone drugs, that are useful in methods for the treatment and prevention of cardiac injury caused by hypoxia or ischemia. The invention also includes methods for the treatment and prevention of cardiac injury comprising contacting a composition of the invention with a human patient.
PCT/US2005/015742 2004-05-05 2005-05-05 Pyrroloquinoline quinone drugs for treatment of cardiac injury WO2005107871A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002565616A CA2565616A1 (en) 2004-05-05 2005-05-05 Pyrroloquinoline quinone drugs for treatment of cardiac injury
JP2007511607A JP2007536256A (en) 2004-05-05 2005-05-05 Pyrroloquinoline quinone drugs for the treatment of heart injury and methods of use thereof
AU2005240650A AU2005240650A1 (en) 2004-05-05 2005-05-05 Pyrroloquinoline quinone drugs for treatment of cardiac injury
EP05745030A EP1750805A2 (en) 2004-05-05 2005-05-05 Pyrroloquinoline quinone drugs for treatment of cardiac injury

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US56835304P 2004-05-05 2004-05-05
US60/568,353 2004-05-05
US61750804P 2004-10-08 2004-10-08
US60/617,508 2004-10-08

Publications (2)

Publication Number Publication Date
WO2005107871A2 WO2005107871A2 (en) 2005-11-17
WO2005107871A3 true WO2005107871A3 (en) 2006-12-21

Family

ID=34968662

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/015742 WO2005107871A2 (en) 2004-05-05 2005-05-05 Pyrroloquinoline quinone drugs for treatment of cardiac injury

Country Status (5)

Country Link
EP (1) EP1750805A2 (en)
JP (1) JP2007536256A (en)
AU (1) AU2005240650A1 (en)
CA (1) CA2565616A1 (en)
WO (1) WO2005107871A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009535410A (en) * 2006-05-02 2009-10-01 シーエルエフ メディカル テクノロジー アクセラレーション プログラム インコーポレイテッド Pyrroloquinoline quinone and use thereof
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof
CN110870866A (en) * 2018-09-03 2020-03-10 浙江医药股份有限公司新昌制药厂 Application of pyrroloquinoline quinone in preparation of medicine for preventing and treating acute altitude reaction and acute altitude hypoxia injury
IT202000025603A1 (en) * 2020-10-28 2022-04-28 Longeva Health S R L COMPOSITION FOR PREVENTING AND TREATING HEART FAILURE AND/OR HEART FAILURE

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998043621A1 (en) * 1997-03-31 1998-10-08 The Children's Medical Center Corporation Nitrosylation to inactivate apoptotic enzymes
WO2003097056A1 (en) * 2002-05-15 2003-11-27 Clf Medical Technology Acceleration Program, Inc. Pyrroloquinoline quinone for treatment of cardiac injury and methods of use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998043621A1 (en) * 1997-03-31 1998-10-08 The Children's Medical Center Corporation Nitrosylation to inactivate apoptotic enzymes
WO2003097056A1 (en) * 2002-05-15 2003-11-27 Clf Medical Technology Acceleration Program, Inc. Pyrroloquinoline quinone for treatment of cardiac injury and methods of use thereof

Also Published As

Publication number Publication date
EP1750805A2 (en) 2007-02-14
AU2005240650A1 (en) 2005-11-17
JP2007536256A (en) 2007-12-13
WO2005107871A2 (en) 2005-11-17
CA2565616A1 (en) 2005-11-17

Similar Documents

Publication Publication Date Title
WO2004006858A3 (en) Compounds, compositions, and methods employing same
WO2005067546A3 (en) Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
WO2006096439A3 (en) Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
WO2006116221A3 (en) Therapeutic combinations for the treatment or prevention of psychotic disorders
WO2006102610A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007061661A3 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2008148074A3 (en) Inhibitors of mtor and methods of treatment using same
WO2006124748A3 (en) Multicyclic compounds and methods of their use
WO2007137071A3 (en) Compositions of r(+) and s(-) pramipexole and methods of using the same
TW200608979A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
MY143795A (en) Tetrahydropyridoindole derivatives
WO2008097924A3 (en) Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
WO2007028022A3 (en) Novel compounds as p2x7 modulators and uses thereof
WO2005091853A3 (en) Methods and compositions for treating il-13 related pathologies
EP1753777A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF HIV INFECTION USING TRIM5a
WO2007100758A3 (en) Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
WO2005009460A3 (en) Pharmaceutical composition comprising activin a, alk-4 or derivatives thereof for the treatment of ophthalmic disorders or cancer
WO2007130509A3 (en) Pyrroloquinoline quinones and use thereof
WO2005086656A3 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
DE60335647D1 (en) PYRROLOQUINOLINE QUINONE AND A BETABLOCKER FOR THE TREATMENT OF ISCHEMIA OR REPERFUSION DAMAGE
WO2005118609A3 (en) Small molecule stimulators of neuronal growth
WO2008016640A3 (en) Use of poloxamer for the prevention and/or treatment of heart failure
WO2006099410A3 (en) Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
WO2006034001A3 (en) Methods of treating hiv infection
WO2006009874A3 (en) Methods and compositions for treatment of excess nitric oxide or cyanide toxicity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007511607

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2565616

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2005240650

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005745030

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2005240650

Country of ref document: AU

Date of ref document: 20050505

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005240650

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005745030

Country of ref document: EP